N/A N=130 Staging and Outcome Depending on Surgical Treatment in Adenocarcinomas of the Oesophagogastric Junction
Esophageal Carcinoma
Primary: Overall Survival — 12; 11; 13 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=60 Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer
Esophageal Cancer · Gastric Cancer
Primary: Reponse Rate at Time of Surgery by Tissue — 40 participants
Phase 2 N=3 Epacadostat and Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Junction or Gastric Cancer
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma · Recurrent Esophageal Carcinoma
Primary: Progression-free Survival (PFS) — 0 Participants
Phase 2 N=113 A Phase 1b/2 Study of MEDI4736 With Tremelimumab, MEDI4736 or Tremelimumab Monotherapy in Gastric or GEJ Adenocarcinoma
Gastric or Gastroesophageal Junction Adenocarcinoma
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) in Phase 1b — 6; 2 Participants
Phase 2 N=80 Study of Pembrolizumab in Subjects With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Who Progressed After First-Line Therapy With Platinum and Fluoropyrimidine: Integration of Molecular Subtypes Through Integrative Genomic Analysis
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: RR — 15 Participants
Phase 2 N=40 Study of Irinotecan and Docetaxel in Patients With Metastatic or Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Cancer · Esophageal Neoplasms
Primary: Objective Response (Complete, Partial, Stable and Progression) — 0; 7; 22; 9 participants
Phase 2 N=58 Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ)
Stomach Cancer · Gastric Cancer
Primary: Complete Pathologic Response Rate — 14 percentage of participants
N/A N=367 Human Epidermal Growth Factor Receptor 2 (HER-2) Status in Gastric and Gastro-Esophageal Junction (GEJ) Carcinoma
Gastric Cancer, Gastroesophageal Junction Cancer
Primary: Simple Kappa Coefficient of Human Epidermal Growth Factor Receptor 2 (HER-2) Status Between Local and Centralized Laboratory Assessments — 0.69 kappa coefficient…
Phase 3 N=355 Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Gastric Cancer · Adenocarcinoma
Primary: Overall Survival (OS) — 5.2; 3.8 months — p=0.0473
Phase 2 N=18 Neo-adjuvant Chemotherapy in Locally Advanced Gastric Cancer
Stage T3-4NxM0 Gastric Cancer
Primary: Number of Participants With Pathological Response — 0; 4; 8; 3 Participants
Phase 3 N=1,007 Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Gastric Cancer · Gastroesophageal Junction Cancer
Primary: Event-free Survival (EFS) Per Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) - Pembrolizumab+XP/FP and Placebo+XP/FP Treatment Arms — 44.4; 25.7 Months…
Phase 2 N=26 Pharmacogenomically Selected Treatment for Gastric and Gastroesophageal Junction (GEJ) Tumors
Stomach Neoplasms · Esophageal Neoplasms
Primary: Overall Response Rate (ORR) — 39.1 percentage of participants
Phase 2 N=58 Gefitinib in Treating Patients With Recurrent or Metastatic Esophageal or Gastroesophageal Junction Cancer
Esophageal Cancer
Primary: The Number of Patients With Complete or Partial Response Rate of Single Agent ZD1839 in a Patient Population With Recurrent or Metastatic Cancer of the Esophagus or…
Phase 2 N=144 Study to Evaluate the Efficacy and Safety of Andecaliximab Combined With Nivolumab Versus Nivolumab Alone in Adults With Unresectable or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Objective Response Rate (ORR) — 9.7; 6.9 percentage of participants — p=0.8
Phase 2 N=60 Oxaliplatin, Capecitabine and Avastin for Metastatic Esophagogastric Adenocarcinoma
Esophageal Neoplasms · Stomach Neoplasms · Neoplasm Metastasis
Primary: Median Progression-Free Survival (PFS) — 6.97 survival time in months
Phase 3 N=15 Prospective Randomized Trial Comparing Gastrectomy, Metastasectomy Plus Systemic Therapy Versus Systemic Therapy Alone: GYMSSA Trial
Gastric Cancer
Primary: Overall Survival in Patients With Limited Metastatic Gastric Carcinoma: Arm I — 19; 11; 11; 4 Months
Phase 2 N=150 Docetaxel+Oxali+/-Cetux Met Gastric/GEJ
Gastric Cancer Adenocarcinoma Metastatic
Primary: Progression-free Survival — 4.7; 5.1 months
Phase 2 N=191 A Study of Ramucirumab in Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Metastatic Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) — 6.34; 6.74 Months — p=0.698
Phase 2 N=48 Study of Docetaxel, Cisplatin, and Fluorouracil (Modified DCF) With Bevacizumab in Patients With Unresectable or Metastatic Gastroesophageal Adenocarcinoma
Stomach Neoplasms · Esophageal Neoplasms
Primary: 6 Month Progression Free Survival — 79 percentage of participants
Phase 2 N=35 Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma
Stomach Cancer · Gastric (Stomach) Cancer · Neoplasm of Cardioesophageal Junction
Primary: Progression-Free Survival (PFS) — 9 Participants
Phase 1 N=25 A Pilot Study of FOLFIRINOX in Combination With Neoadjuvant Radiation for Gastric and GE Junction Cancers
GastroEsophageal Cancer
Primary: The Completion Rate of Chemotherapy in Combination With Chemoradiation — 23 Participants
Phase 3 N=592 A Study of Pembrolizumab (MK-3475) Versus Paclitaxel for Participants With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma That Progressed After Therapy With Platinum and Fluoropyrimidine (MK-3475-061/KEYNOTE-061)
Gastric Adenocarcinoma · Gastroesophageal Junction Adenocarcinoma
Primary: Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR) in Programmed…
Phase 2 N=39 FOLFOX-A in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma
Gastro-Esophageal Junction Adenocarcinoma · Gastric Cancer
Primary: Objective Response Rate — 15 Participants
Phase 2 N=98 S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction
Esophageal Cancer
Primary: Pathological Complete Response — 26 participants
Phase 2 N=36 Perioperative Chemo and Pembrolizumab in Gastric Cancer
Gastric Cancer · Adenocarcinoma of the Gastroesophageal Junction
Primary: Pathologic Complete Response (pCR) Rate — 7 Participants
Phase 2 N=40 Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer
Gastric Cancer
Primary: Best Overall Response (BOR) Rate - Independent Review Committee (IRC) Assessments — 40 percentage of participants
Phase 2 N=17 Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma
Esophagogastric Adenocarcinoma
Primary: Overall Response Rate, as Assessed by Radiographic Imaging — 3 Participants
Phase 2 N=98 Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients
Gastrointestinal Diseases
Primary: Maximum Tolerated Dose (MTD) — 50 mg/m^2
Phase 3 N=738 Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)
Gastric Neoplasms · Gastroesophageal Junction Adenocarcinoma
Primary: Progression Free Survival (PFS) Per RECIST 1.1 Assessed by BICR — 10.0; 8.1 Months — p=0.0002
Phase 2 N=39 FOLFOX With Bevacizumab in Metastatic or Unresectable Gastroesophageal and Gastric Cancer
Gastroesophageal Cancer · Gastric Cancer
Primary: Progression Free Survival — 7.8 months